Bonney's blue paint BP 1980
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 6 · 1988–2026
Showing the 50 most relevant studies, sorted by most relevant.
Marina Bandeira, Marcelo Giovanela, Mariana Roesch‐Ely, et al.
Sustainable Chemistry and Pharmacy, 2020
Eliška Sudová, Jana Machová, Zdeňka Svobodová, et al.
Veterinární Medicína, 2007
Navid Rabiee, Rajni Sharma, Sahar Foorginezhad, et al.
Environmental Research, 2023
- Water Purification
- Metals, Heavy
- Nanostructures
Michel Mitov
Soft Matter, 2017
- Liquid Crystals
- Biopolymers
- Mechanical Phenomena
L.M. Soltys, Ostap Olkhovyy, Тетяна Татарчук, et al.
Magnetochemistry, 2021
Nirav P. Raval, Prapti U. Shah, Nisha K. Shah
Applied Water Science, 2016
Pingping Wu, Jingxia Wang, Lei Jiang
Materials Horizons, 2019
S. Mennel, C. Meyer, J. Schmidt, et al.
Developments in ophthalmology, 2008
The use of vital dyes during vitrectomy allows easier removal of less recognizable structures like epiretinal membranes or the internal limiting membrane (ILM). In recent years, numerous studies have investigated the use of indocyanine green (ICG), trypan blue (Membrane Blue), triamcinolone, autologous blood and presently trityl dyes such as patent blue V (PBV, Blueron), crystal violet and brilliant blue G (BBG, Brilliant Peel) in chromovitrectomy. Reports on potential risks of these dyes, especially ICG, such as reduced visual acuity, possible visual field defects or alterations of the retinal pigment epithelium (RPE) limited their application. A systematic review of the literature up to July 2007 was performed using Medline (http://www.ncbi.nlm.nih.gov/ PubMed/) where we specifically searched for relevant information regarding the laboratory as well as clinical use of PB and BBG. To evaluate the effect of PB and BBG on the RPE, PB and BBG have been added to an in vitro model of the outer blood-retinal barrier to assess dye-associated barrier properties. Two concentrations of PB (2.4 and 1.2 mg/ml) and BBG (0.25 and 2.4 mg/ml) were investigated. To simulate in vivo conditions of a fluid-filled eye and an air-filled eye the dyes were added either to the culture medium or directly to the RPE cells where they remained for 2.5 min. To determine barrier properties, transepithelial resistance (TER) was measured at 3 days of follow-up. Ultrastructural integrity of RPE cells was evaluated by transmission electron microscopy. Following application of PB, barrier properties in the fluid- as well as in the air-filled eye showed only mild, transient and no significant decrease in TER. BBG did not cause a breakdown of the outer bloodretinal barrier at the concentration of 0.25 mg/ml in the model of the fluid-filled eye. The concentration of 2.4 mg/ml in the model of the fluid-filled eye as well as both concentrations in the model of the air-filled eye showed a minor decrease after 1.5 h, which was no longer observed after 24 h. Transmission electron microscopy did not show any dye-associated ultrastructural alterations to the RPE cells. In clinical use, PB showed only mild staining of epiretinal membranes and moderate staining of the ILM. Although BBG did not stain epiretinal membranes, it represents an appropriate candidate for the future, as BBG has a high affinity for the ILM. The use of trityl dyes in the posterior eye segment seems to be safe concerning damage to the RPE and its barrier function, especially when the dye is applied to the fluid-filled eye
Abstract licence: CC BY
Pantaleo Raimondi, C. Benabderrahmane, P. Berkvens, et al.
Communications Physics, 2023
J. Bumpus, B. J. Brock
Applied and Environmental Microbiology, 1988
- Peroxidases
- Basidiomycota
- Biodegradation, Environmental
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.